Keeping America’s lead in biotech depends on fixing what's broken about the policy status quo — and not breaking what works, ...

The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, which has invested heavily in cell and gene therapy technology.

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

Swiss biotech Relief Therapeutics is slated to enter a reverse merger with private U.S. biotech Renexxion and forge ahead with the latter’s gastrointestinal pipeline. Rare-disease-focused Relief would ...

Washington and Wall Street have spent decades debating U.S. dependence on China for chips, consumer electronics and manufacturing. Now, China is poised to disrupt another major industry, one that is ...

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. The NIH has blocked access to some health and genomics databases ...

"We are also seeing improvement in US biotech funding, as well as higher M&A and IPO activity, which are leading indicators ...

Jyong Biotech Ltd. (MENS) has filed proposed terms to raise $18.8 million from the sale of its common stock in an IPO, according to an amended F-1/A SEC registration statement. The firm is developing ...

A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...